We also demonstrated that efficiently blocking C3d+ A1 astrocyte conversion using semaglutide, a glucagon-like peptide-1 receptor (GLP-1R) agonist, reduces ischemia-induced BBB disruption and improves neurobehavioral recovery. Here, GLP1R is linked to ischemia.